Results (3620)
EMA’s human medicines committee (CHMP) recommended 12 medicines for approval at its March 2024 meeting.
The Accelerating Clinical Trials in the EU (ACT EU) initiative has established a multi-stakeholder platform (MSP) aimed at improving the environment for clinical trials across the European Union (EU).
Outcomes of the Committee for Veterinary Medicinal Products (CVMP) meeting.
PRAC finds no link between mRNA COVID-19 vaccines and postmenopausal bleeding
The Data Analysis and Real World Interrogation Network DARWIN EU seeks ten new data partners in 2024.
EMA has recommended granting a marketing authorisation in the European Union (EU) for Voydeya, the first oral treatment for patients with paroxysmal nocturnal haemoglobinuria (PNH) who continue to have haemolytic anaemia (low levels of red blood cells) despite treatment with a C5 complement inhibitor (eculizumab or ravulizumab).
EMA has recommended granting a marketing authorisation in the European Union for a new therapy for the treatment of adult patients with amyotrophic lateral sclerosis (ALS), a rare and often fatal disease that causes muscles to become weak and leads to paralysis. Qalsody (tofersen) is indicated for the treatment of adults with ALS, who have a...
EMA’s human medicines committee (CHMP) recommended 10 medicines for approval at its February 2024 meeting.
Countries that have decreased their consumption of antibiotics in both animals and humans have seen a reduction in antibiotic-resistant bacteria.